The Dynamics of Naturally Acquired Immune Responses to *Plasmodium falciparum* Sexual Stage Antigens Pfs230 & Pfs48/45 in a Low Endemic Area in Tanzania

Teun Bousema¹,², Will Roeffen³, Hinta Meijerink³, Harry Mwerinde⁴, Steve Mwakalinga²,⁵, Geert-Jan van Gemert³, Marga van de Vegte-Bolmer³, Frank Mosha²,⁶, Geoffrey Targett¹, Eleanor M. Riley¹, Robert Sauerwein³, Chris Drakeley¹,²*

¹Department of Immunology & Infection, Faculty of Infectious & Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom, ²Joint Malaria Programme, Moshi, Tanzania, ³Department of Medical Microbiology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands, ⁴TPC District Designated Hospital, Tanzania Plantation Company, Lower Moshi, Tanzania, ⁵Department of International Health, Immunology, and Microbiology, University of Copenhagen, Copenhagen, Denmark, ⁶Kilimanjaro Clinical Research Institute, Moshi, Tanzania

**Abstract**

**Background:** Naturally acquired immune responses against sexual stages of *P. falciparum* can reduce the transmission of malaria from humans to mosquitoes. These antigens are candidate transmission-blocking vaccines but little is known about the acquisition of sexual stage immunity after exposure to gametocytes, or their longevity and functionality. We conducted a longitudinal study on functional sexual stage immune responses.

**Methodology/Principal Findings:** Parasitaemic individuals (n = 116) were recruited at a health centre in Lower Moshi, Tanzania. Patients presented with gametocytes (n = 16), developed circulating gametocytes by day 7 (n = 69) or between day 7 and 14 (n = 10) after treatment or did not develop gametocytes (n = 21). Serum samples were collected on the first day of gametocytaemia and 28 and 84 days post-enrolment (or d7, 28, 84 after enrolment from gametocyte-negative individuals). Antibody responses to sexual stage antigens Pfs230 and Pfs48/45 were detected in 20.7% (72/348) and 15.2% (53/348) of the samples, respectively, and were less prevalent than antibodies against asexual stage antigens MSP-1, AMA-1 increased with longer duration of gametocyte exposure and had an estimated half-life of approximately 3 months. Membrane feeding experiments demonstrated a strong association between the prevalence and concentration of Pfs230 and Pfs48/45 antibodies and transmission reducing activity (TRA; p < 0.01).

**Conclusions/Significance:** In a longitudinal study, anti-Pfs230 and Pf48/45 antibodies developed rapidly after exposure to gametocytes and were strongly associated with transmission-reducing activity. Our data indicate that the extent of antigen exposure is important in eliciting functional transmission-reducing immune responses.

**Citation:** Bousema T, Roeffen W, Meijerink H, Mwerinde H, Mwakalinga S, et al. (2010) The Dynamics of Naturally Acquired Immune Responses to *Plasmodium falciparum* Sexual Stage Antigens Pfs230 & Pfs48/45 in a Low Endemic Area in Tanzania. PLoS ONE 5(11): e14114. doi:10.1371/journal.pone.0014114

**Editor:** Lorenz von Seidlein, Menzies School of Health Research, Australia

**Received** July 20, 2010; **Accepted** September 16, 2010; **Published** November 29, 2010

**Copyright:** © 2010 Bousema et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** This study was supported by a Wellcome Trust research fellowship to CJD (#063516). JTB was supported by the European Union FIGHTMAL project, receiving funding from the European Community’s Seventh Framework Programme [FP7/2007–2013] under grant agreement PIAP-GA-2008-218164. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** Dr Mwerinde works at a hospital within the TPC grounds but is not employed by them. He is employed by the government. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.

* E-mail: chris.drakeley@lshtm.ac.uk

**Introduction**

Recent successes in eliciting transmission-reducing immune responses with malaria transmission-blocking vaccines (MTBV) in animal models [1,2,3,4] have fuelled interest in future deployment of these vaccines as part of malaria control and elimination strategies [5,6]. Understanding the dynamics of naturally acquired transmission-reducing immune responses will assist in the future deployment of MTBV in endemic populations. The transmission of malaria depends on the presence of mature sexual stage parasites, gametocytes, in the human peripheral blood. Once ingested by a mosquito taking a blood meal, gametocytes will form male microgametes and female macrogametes that after fertilization and zygote formation develop into ookinetes that penetrate the mosquito midgut wall to form an oocyst underneath the basal lamina of the midgut. Each oocyst produces thousands of sporozoites, rendering the mosquito infectious to humans. The infectiousness of gametocytes to mosquitoes depends on their density [7,8,9] and level of maturation [10] but also on mosquito density [7,8,9] and level of maturation [10] but also on mosquito [11] and human immune responses [12]. Human transmission-reducing antibodies are ingested by Anopheline mosquitoes together with gametocytes and can interfere with zygote formation and, as a consequence, further development of parasites in the mosquito vector. MTBV are designed to induce such antibody responses to reduce the infectiousness of gametocytes to mosquitoes or even block transmission completely [6,13,14].
The three most promising MTBV candidates for *Plasmodium falciparum* so far are based on the induction of antibody responses against parasite antigens Pf6230, Pf640/45 and Pf6225 [1,2,3,4,15]. Pf640/45 and Pf6230 are expressed on the surface of gametes and are involved in the fertilization of macrogametocytes by microgametes [5]; Pf6225 is a postfertilization antigen expressed on the surface of ookinetes [4], and plays a role in the traversal of the mosquito midgut epithelium [16]. The gamete surface molecules Pf640/45 and Pf6230 are also expressed in gametocytes circulating in the human blood and antibody responses against these antigens are detected in naturally exposed individuals [12,17,18]. This makes it possible to study the nature and duration of sexual-stage specific immunity in naturally infected individuals [5]. Naturally acquired sexual stage-specific antibody responses may be acquired after exposure to gametocytes [12] and rapidly induced as part of the initial response to infection [19,20]. In contrast to antibodies against pre-erythrocytic and blood-stage antigens [19,21,22], the prevalence of sexual-stage specific antibodies does not increase with age [23,24]. Little is known about the rate of induction or longevity of sexual-stage antibody responses and this may be important for natural boosting of any vaccine induced response.

Here, we determine the acquisition, longevity and functionality of sexual stage specific antibody responses in a longitudinal study in an area of low endemicity in Tanzania.

**Methods**

Ethics permission was received from the ethical committees of the National Institute for Medical Research, the Kilimanjaro Christian Medical Centre, and the London School of Hygiene and Tropical Medicine. Written consent was obtained from all participants or their parents/guardians prior to enrolment in the study.

Individuals were recruited from January 2003 till December 2004 at the health centre in Msiitu wa Tembo and the clinic of the nearby sugar plantation, Tanzania Plantation Company, in Lower Moshi (latitude 3° 33’ S; longitude 37° 17’ E). The area of Lower Moshi lies at an altitude of ~700 meters between the Maasai savannah and foothills of Mount Kilimanjaro. Malaria transmission at the time the study was conducted was hypoendemic with an estimated entomologic inoculation rate of 3.4 (95% CI 0.7–9.9) infectious bites per person per year [25] and peaks in malaria incidence following the rains in March–May and October–November. The low level of malaria transmission was considered to be beneficial for the current study objectives because of the low likelihood of re-infections during follow-up. Individuals were eligible for recruitment if they were found parasitaemic after examination of 100 high power microscopic fields. Slides were read for asexual parasites and gametocytes separately, each by two technicians. Asexual parasites and gametocytes were enumerated against 200 and 500 leukocytes, respectively, and expressed as density/µL assuming an average leukocyte count of 8,000/µL. Parasitaemic individuals were treated with sulphadoxine-pyrimethamine (SP) according to national guidelines at that time and seen on day 7, 14, 28, 42, 56 and 84 after initiation of treatment. On days 7, 14, 28, and 84, a slide was taken to determine exposure to asexual parasites and gametocytes; a rapid diagnostic test (Paracheck®, Orchid Biomedical Systems, India) was used to detect infection qualitatively on day 42 and 56. On the first day of gametocytaemia and on days 28 and 84 after enrolment, a venous blood sample was taken for serological analyses and standard membrane feeding assay. Samples were also taken from individuals who did not present with microscopically detectable gametocytes in the 28 days post treatment. For these individuals, sampling was done on day 7, 28 and 84 after enrolment. This observational study was exploratory in nature and no formal sample size calculation was done.

**Enzyme-linked immunosorbent assays (ELISAs)**

**Antigen preparation.** Mature gametocytes of *P. falciparum* (NF54 strain) were produced in an automated static culture system [26], isolated on 63% Percoll [no. 17-0891-01, GE Healthcare, Uppsala, Sweden] and stored at −70°C until used. The NF54 gametocytes were extracted in 25 mM Tris-HCl, pH 8.0, supplemented with 150 mM NaCl, 1.0% sodium deoxycholate, and 1 mM phenylmethylsulfonyl fluoride. Samples were centrifuged at 13,000 x g for 5 minutes at room temperature to remove insoluble debris and the supernatant was used as the source of whole parasite antigen.

**ELISA for sexual stage antigens Pf6230 and Pf640/45.** The presence of human antibodies to Pf640/45 and Pf6230 was determined by a two-site ELISA as described previously [19]. Briefly, 96-well microtiter plates (Sterilin-ELISA plates [no. 53011; International Medical Products B.V., Zutphen, The Netherlands]) were coated with anti-Pf6230 mouse monoclonal antibody (MAb) 63P2A2 (5 µg/mL) in phosphate-buffered saline (PBS), pH 7.4. For Pf640/45, the plates were coated with rat MAb 85RF45.3. Free sites were blocked with 5% low-fat dry milk [Marvel, Premier International Foods Ltd., Spalding, United Kingdom] in PBS. Pf640/45 and Pf6230 were captured from a gametocyte extract (250,000 parasite equivalents/well) for half of the wells; the other half was tested without antigen. Serum samples (1: 100 dilution) were added to the wells and incubated for two hours. Bound IgG antibodies were detected by horseradish peroxidase–labeled goat anti-human IgG [31412; Pierce Biotechnology, Inc., Rockford, IL]. The wells were washed three times with PBS and subsequently incubated with tetramethylbenzidine substrate (TMB) solution for 20 minutes. The colour reaction was stopped with 2 N H2SO4, and optical density (OD) was read at 450 nm [Anthos 2001 microplate reader; Labtec BV, Heerhugowaard, The Netherlands]. All incubations were carried out at room temperature. All serum samples were tested in duplicate with a concurrent positive control and a minimum of four negative (Dutch blood bank donor) controls per plate. The OD was adjusted for background reactivity by subtracting the OD without antigen.

**ELISA for asexual stage antigens Apical Membrane Antigen-1 (AMA-1) and Merozoite Surface Protein-1,9 (MSP-1,9).** Anti-MSP-1,9 and anti-AMA-1 human IgG antibodies were detected by ELISA using standard methodology [21,27], using the sera at 1/1000 and 1/2000 dilution, respectively. The OD was standardized against a positive control that was included on each plate.

For sexual and asexual stage ELISAs, all samples from one individual were included on the same plate; a cut-off above which samples were deemed antibody positive was defined using a mixture model as previously described [27]. The distribution of OD values was subsequently fitted as the sum of two Gaussian distributions (a narrow distribution of sero-negatives and a broader distribution of sero-positives) using maximum likelihood methods. The mean OD of the Gaussian corresponding to the sero-negative population plus three standard deviations was used as the cut-off for sero-positivity.

**Standard membrane feeding assay (SMFA)**

Twenty-five individuals were selected for membrane feeding experiments. The selection was done randomly; the only selection criterion was the availability of a complete set of three serum
samples from the first day of patent gametocytaemia, day 28 and day 84 after enrolment. Seventy-five serum samples from these 25 individuals were purified for the SMFA using the Protein G HP Multitrap [GE Healthcare, Uppsala, Sweden: Code no 28-9031-35] according to the manufacturer’s instructions. 200µL plasma was diluted with 400µl binding buffer and added in triplicate to the 96-well plate. The flow through (FT) still contains antibody and can be isolated using the same procedure twice. The eluted and neutralized samples were combined, diluted to 20ml with MilliQ water and subsequently concentrated to the original starting volume using centrifugal concentration tubes [Vivaspin 20, Sartorius AG, Gottingen, Germany: Code no VS2021]. The purified field samples were used for testing in the ELISAs, or added to freeze dried FCS (90µl) tubes for testing in the membrane feeding assay. The yield of protein varied from 2 to 4 mg/ml and a mean recovery of 76.2% (standard deviation of 13.9%) varied between 51% and 97%.

Experimental infections of mosquitoes were carried out as previously described [28,29] including samples from the same individual in the same experiment. Three to five day old *A. stephensi* were allowed to feed on cultured *P. falciparum* gametocytes of NF54, in the presence of purified control serum or test sample at a final dilution of 1:3 in the feeder. After feeding, blood-fed mosquitoes were kept at 26°C. Surviving mosquitoes were dissected seven days later, and oocyst counts were made for each sample. Midguts of 20 mosquitoes were examined for oocysts. The experiment was considered valid when at least 70% of the mosquitoes feeding on control sera were infected. The observed transmission reducing activity (TRA) of serum was determined as the percentage reduction in arithmetic mean oocyst number in test samples as compared to paired controls [30].

**Statistical analysis**

Data was double entered in MS Access and imported into STATA version 11 (StataCorp LP, College Station, TX, USA). Binary variables were analysed by Chi-square, Fisher’s Exact or Chi-square test for trend; odds ratio’s with 95% confidence intervals were presented where appropriate. The association between continuous variables was determined by the nonparametric Spearman correlation coefficient. To determine the longevity of the antimalarial antibody responses, we analysed the change in concentrations of antibodies to Pf230 and Pf48/45 between day 28 and day 84 in relation to time since the last documented exposure to gametocytes (day 0–28). The longevity of antibody responses to MSP-119 and AMA-1 was estimated in a similar manner, using the change in antibody concentration between day 7 and day 84 in relation to time since the last documented exposure to asexual parasites (day 0). The half-life of the antibody response was analysed in a repeated measurements analysis using log-linear regression model including adjusting for associations between multiple data points from the same subjects. Half-lives were calculated from the estimated decay rate and the boundaries at 95% confidence interval obtained from the mixed-effects model [31]. A curve was fitted for Pf230 and Pf48/45 antibody concentration in relation to the reduction in oocyst numbers using GraphPad Prism software 4.02 (GraphPad Software, Inc., CA, USA).

**Results**

Sexual stage antibody responses were examined in 116 individuals who presented with asexual *P. falciparum* parasites at the clinic and who had gametocytes at enrolment (n = 16), developed gametocytes on day 7 (n = 69) or day 14 (n = 10) after treatment with SP or did not develop on any day gametocytes after treatment (n = 21) (table 1). After clearance of the initial infection, no re-infections were detected during follow-up by microscopic slide (day 7, 14, 28, 84) or by rapid diagnostic test (day 42, 56). Anti-Pf230 antibodies were detected in 20.7% of the samples (72/348); 25.9% (30/116) of the participants showed Pf230 seroreactivity on at least one time-point during the study. Antibodies against Pf48/45 were detected in 15.2% (33/348) of the samples; 27.6% (32/116) of the participants showed Pf48/45 seroreactivity on at least one occasion. There was a strong positive association between the prevalence of gametocytes (p<0.001) and concentration of antibodies against Pf230 and Pf48/45 (Spearman correlation coefficient 0.66, p<0.001). Recognition of Pf230 and Pf48/45 increased with age in our population (figure 1). Antibody responses to asexual stage antigens AMA-1 and MSP-119 were detected in 52.4% (129/246) and 48.1% (137/285) of the samples and antibody prevalence increased with age (figure 1).

**The induction and duration of sexual stage antibody responses**

Sexual stage antibody prevalence and concentration were related to recent cumulative exposure to gametocytes prior to sampling. There was no statistically significant association between the duration of gametocyte exposure and Pf230 antibody prevalence on day 7 after enrolment (OR 1.74, 95% CI 0.79–3.87, p = 0.17). Pf230 antibodies on day 28 after enrolment were less prevalent in individuals who had no microscopically detectable gametocytes between day 0 and day 28, more prevalent in those who had gametocytes for ≥1 week (trend: OR 2.44, 95% CI 1.11–5.36, p = 0.026). A similar association was observed for Pf48/45 antibodies on day 7 (trend: OR 2.62, 95% CI 0.98–7.01, p = 0.054) and on day 28 (OR 2.73, 95% CI 1.19–6.35, p = 0.017) after adjustment for age (figure 2; table 2). Similarly, an increase in day 28 antibody concentrations (optical density in the ELISA) for Pf230 (β = 0.12, 95% CI 0.01–0.23, p = 0.046) and Pf48/45 (β = 0.060, 95% CI 0.00–0.12, p = 0.066) was observed across these gametocyte carriage categories, after adjustment for age (table 2). These trends disappeared by day 84 for Pf230 antibody prevalence (OR

---

**Table 1. Demographic information.**

| Age, median (IQR) | 10 (5–18) |
|-------------------|-----------|
| Gender, % female  | 42.1 (48/114) |
| Asexual parasite density/µL, median (IQR) | 133 (34–812) |
| Proportion presenting with fever (≥37.5°C, %/n/N) | 56.6 (64/113) |
| Clinical malaria (parasite density >1000/µL & fever) | 11.5% (13/113) |
| First day of gametocytaemia | |
| Never | 18.1 (21/116) |
| Prior to treatment | 13.8 (16/116) |
| 7 days post initiation treatment | 59.5 (69/116) |
| 14 days post initiation treatment | 8.6 (10/116) |
| 28–84 days post initiation treatment | 0.0 (0/116) |
| Duration of gametocytaemia | |
| <2 weeks | 75.0 (69/92) |
| 2–3 weeks | 16.3 (15/92) |
| >3 weeks | 8.7 (8/92) |

DOI:10.1371/journal.pone.0014114.t001
Anti-Gametocyte Antibodies

Figure 1. Antibody responses to Pfs230 and Pfs48/45 in relation to age. Bars indicate antibody prevalence in different age-groups, error bars the upper limit of the 95% confidence interval. Multiple observations are included per individual. Antibody responses to Pfs230 (p = 0.006), Pfs48/45 (p = 0.008), AMA-1 (p < 0.001) and MSP-119 (p = 0.013) increased with increasing age, after adjusting for correlations between observations from the same individual. The number of observations for Pfs230, Pfs48/45, AMA-1 and MSP-119 were 69, 69, 31, 32 (<5 years), 168, 168, 134, 134 (5–14 years), 111, 111, 119, 81 (≥15 years). The asterisks indicates a statistically significant positive trend between antibody responses and age in all categories (p < 0.05).

doi:10.1371/journal.pone.0014114.g001

Figure 2. Pfs230 and Pfs48/45 antibody prevalence in relation to the duration of exposure to gametocytes during follow-up. Bars indicate total antibody prevalence in individuals who did not develop gametocytes during follow-up (clear bars), individuals who had gametocytes detected by microscopy on only one occasion (shaded bars, less than one week) and individuals who had gametocytes detected on at least two consecutive visits that were at least 7 days apart (filled bars, ≥1 week); error bars indicate the upper limit of the 95% confidence interval. On day 7 and 28 after enrolment, the number of observations for Pfs230, Pfs48/45, AMA-1 and MSP-119 were 19, 69, 25. The asterisks indicates a statistically significant positive trend between antibody responses and duration of exposure to gametocytes (p < 0.05).

doi:10.1371/journal.pone.0014114.g002

1.29, 95% CI 0.52–3.20, p = 0.58) and concentration (β = 0.055, 95% CI -0.03–0.14, p = 0.24) and for Pfs48/45 antibody prevalence (OR 1.93, 95% CI 0.46–8.14, p = 0.37) and concentration (β = 0.039, 95% CI 0.00–0.08, p = 0.074). Although sexual stage antibody prevalence was least common in those who did not develop gametocytes during follow-up (p < 0.001), there was a borderline significant increase in the prevalence of both Pfs230 (p = 0.076) and Pfs48/45 antibodies (p = 0.14) between day 7, 28, and 84 in this group. There was no association between the duration of gametocyte exposure and the antibody prevalence or concentration for AMA-1 (p = 0.42) and MSP-119 (p = 0.48) on any of the days of sampling.

The decay of Pfs230 and Pfs48/45 antibody responses was determined in individuals who had serum samples collected on day 28 and day 84 and who were antibody positive on day 28 without evidence for continued exposure to gametocytes or re-infection with asexual parasites after day 28. For Pfs230 antibodies, 60 paired observations were available for 30 individuals and the half-life of antibody responses was estimated at 92.6 (95% CI 74.7–122.0) days. This half-life of Pfs230 antibodies appeared shorter in children below 10 years of age (73.9 days, 95% CI 58.6–99.9) compared to adults (100.5 days, 95% CI 76.2–147.9) although not statistically significant (p = 0.10). For Pfs48/45, 52 paired observations were available from 26 individuals and the half-life of antibody responses was estimated at 83.0 (65.8–112.3) days. Similarly for Pfs48/45, the half-life of antibody responses appeared shorter in children below 10 years of age (70.2 days, 95% CI 65.7–144.0) although not statistically significant (p = 0.25).

The half-lives for Pfs230 and Pfs48/45 antibody responses were similar to those of responses against AMA-1 (97.7 days, 95% CI 78.6–129.1; based on 140 observations from 52 individuals) and MSP-119 (52.4 days, 95% CI 44.5–63.6; 145 observations from 52 individuals). AMA-1 and MSP-119 antibody responses declined gradually after enrolment (p ≤ 0.001).

The functionality of sexual stage antibody responses

Seventy-five samples from 25 individuals were included in the SMFA (table 3), giving an overall median reduction of oocyst numbers of 19.4% (IQR 0–66.7). Of the 25 individuals who were included in the SMFA, 6 (24%) were consistent responders to Pfs230 (i.e. Pfs230 antibody positive on all three days), 3 (12%) consistent responders to Pfs48/45 and 3 (12%) consistently reduced transmission ≥50% (TRA ≥50, table 3). Individuals who showed TRA ≥50% on all three occasions were significantly more likely to be a consistent responder to Pfs48/45 (p = 0.002) and Pfs230 (p = 0.065), although the latter was not statistically significant.

When samples were considered individually (n = 75), TRA ≥50% was significantly associated with Pfs230 antibody prevalence (OR 13.14; 95% CI 1.90–91.16, p = 0.009 after adjustment for repeated measures) and Pfs48/45 antibody prevalence (OR 13.04; 95% CI 3.21–577.44, p = 0.005). Twelve samples, derived from six individuals, reduced oocyst numbers ≥90% (TRA ≥90), 100% (12/12) of these were positive for Pfs230 antibodies and 91.7% (11/12) for Pfs48/45 antibodies. We observed a strong positive association between the reduction in oocyst numbers in the SMFA and Pfs230 (Spearman correlation coefficient = 0.65, p < 0.001) and Pfs48/45 antibody concentration (Spearman correlation coefficient = 0.54, p < 0.001). Samples with a higher antibody concentration were more likely to reduce oocyst numbers (figure 3). In a multivariate model that incorporated reactivity to both antigens, there was a strong association between the reduction in oocyst numbers and Pfs230 (β = 35.93, 95% CI 22.35–49.51, p < 0.001) and Pfs48/45 antibody concentration (β = 44.57, 95% CI 20.49–68.85, p < 0.001). Of all samples with an OD > 1 in the Pfs230 ELISA, 83.3% (10/12) showed TRA ≥90%; 87.5% of the samples with an OD > 0.8 in the Pfs48/45 ELISA showed TRA ≥90%. All
### Table 2. Pfs230 and Pfs48/45 antibody prevalence and concentration in relation to the duration of exposure to gametocytes during follow-up.

| Sampling time-point | Gametocyte exposure during follow-up | Pfs230 Antibody prevalence, % (n/N) | Pfs230 Antibody concentration, median OD (IQR) | Pfs48/45 Antibody prevalence, % (n/N) | Pfs48/45 Antibody concentration, median OD (IQR) |
|---------------------|--------------------------------------|--------------------------------------|-----------------------------------------------|--------------------------------------|-----------------------------------------------|
| Day 7               | No                                   | 9.1 (2/20)                           | 0.09 (0.03–0.14)                              | 0.0 (0/22)                           | 0.07 (0.04–0.15)                              |
|                     | <1 week                              | 15.9 (11/69)                         | 0.11 (0.04–0.18)                              | 14.7 (10/69)                        | 0.10 (0.04–0.19)                              |
|                     | ≥1 week                              | 24.0 (6/25)                          | 0.18 (0.08–0.25)                              | 20.0 (5/25)                         | 0.14 (0.06–0.29)                              |
| Day 28              | No                                   | 14.3 (3/21)                          | 0.15 (0.05–0.18)                              | 14.3 (3/21)                        | 0.09 (0.08–0.20)                              |
|                     | <1 week                              | 21.7 (15/69)                         | 0.11 (0.04–0.20)                              | 17.4 (12/69)                        | 0.10 (0.06–0.20)                              |
|                     | ≥1 week                              | 44.0 (11/25)                         | 0.28 (0.11–0.50)                              | 44.0 (11/25)                        | 0.25 (0.08–0.49)                              |
| Day 84              | No                                   | 15.8 (3/19)                          | 0.08 (0.01–0.22)                              | 5.3 (1/19)                          | 0.08 (0.02–0.16)                              |
|                     | <1 week                              | 15.9 (11/69)                         | 0.08 (0.03–0.18)                              | 5.8 (4/69)                          | 0.07 (0.02–0.16)                              |
|                     | ≥1 week                              | 24.0 (6/25)                          | 0.16 (0.07–0.29)                              | 12.0 (3/25)                         | 0.16 (0.04–0.27)                              |

Antibody concentration (optical density, OD, in the ELISA) was adjusted for background reactivity by subtracting the OD without antigen; seropositive and seronegative individuals are included in the table.

- Trend-test, p<0.05;
- 0.05>p<0.1.
- doi:10.1371/journal.pone.0014114.t002

### Table 3. Individual data from repeated membrane feeding experiments.

| ID | Age | First-last day gametocytes | Pfs230 antibody prevalence d7-d28-d84 | Pfs48/45 antibody prevalence d7-d28-d84 | TRA≥50% and ≥90% prevalence d7-d28-d84 |
|----|-----|---------------------------|---------------------------------------|----------------------------------------|----------------------------------------|
| 468| 32  | D0                        | 0-0-0                                 | 0-0-0                                  | 0-0-0                                  |
| 565| 8   | D7                        | 0-0-0                                 | 0-0-0                                  | 0-0-0                                  |
| 842| 5   | D7                        | 0-0-0                                 | 0-0-0                                  | 0-0-0                                  |
| 849| 10  | D7                        | 0-0-0                                 | 0-0-0                                  | 0-0-0                                  |
| 603| 25  | D14                       | 0-0-0                                 | 0-0-0                                  | 0-0-0                                  |
| 649| 13  | D14                       | 0-1-0                                 | 0-0-0                                  | 0-0-0                                  |
| 585| 5   | D7                        | 0-0-0                                 | 1-1-0                                  | 0-0-0                                  |
| 639| 29  | D0–28                     | 1-1-1                                 | 1-1-0                                  | 0-0-0                                  |
| 655| 9   | D7                        | 1-1-0                                 | 1-1-0                                  | 0-0-0                                  |
| 724| 11  | Not detected              | 1-1-1                                 | 0-0-0                                  | 0-0-0                                  |
| 554| 8   | D7                        | 0-0-0                                 | 0-0-0                                  | 1-0-0                                  |
| 527| 8   | D7                        | 0-1-1                                 | 0-0-0                                  | 0-1-0                                  |
| 829| 41  | D7                        | 0-1-1                                 | 1-1-1                                  | 0-1-0                                  |
| 886| 12  | D14–28                    | 1-1-1                                 | 0-1-0                                  | 0-1-0                                  |
| 910| 5   | D7                        | 1-1-0                                 | 0-0-0                                  | 0-1-0                                  |
| 752| 10  | Not detected              | 1-1-1                                 | 0-0-0                                  | 0-1-0                                  |
| 754| 12  | Not detected              | 0-0-0                                 | 0-1-0                                  | 0-1-0                                  |
| 1045|29 | Not detected              | 0-0-0                                 | 0-0-1                                  | 0-0-1                                  |
| 1049|16 | D7–28                     | 0-1-1                                 | 0-1-0                                  | 0-2-0                                  |
| 579| 6   | D7                        | 0-0-0                                 | 0-1-0                                  | 1-1-0                                  |
| 801| 12  | D0                        | 1-1-0                                 | 1-1-0                                  | 2-1-0                                  |
| 902| 10  | D7                        | 0-1-1                                 | 0-1-0                                  | 0-2-2                                  |
| 596| 6   | D0–28                     | 0-1-1                                 | 0-1-1                                  | 1-2-2                                  |
| 889| 46  | D7                        | 1-1-1                                 | 2-2-2                                  |
| 826| 41  | D14                       | 1-1-1                                 | 2-2-2                                  |
Figure 3. The relation between transmission reducing activity and Pfs230 and Pfs48/45 antibody concentration. Transmission reducing activity is plotted as a continuous variable, the reduction in oocyst density in mosquitoes, on the Y-axis. Filled diamonds represent Pfs230 antibody responses; open circles Pfs48/45 antibody responses. The solid line represents the best fit for the association between Pfs230 antibody concentration and % oocyst reduction; % oocyst reduction = 100/1 + 10(0.697-OD Pfs230)*1.44; $R^2 = 0.56$. The dashed line the association between Pfs48/45 antibody concentration and % oocyst reduction: % oocyst reduction = 100/1 + 10(0.490-OD Pfs48/45)*1.84; $R^2 = 0.45$. 

doi:10.1371/journal.pone.0014114.g003

samples (6/6) that fulfilled both these criteria reduced oocyst numbers by ≥90%.

Discussion

In this study, we determined the acquisition, longevity and effectiveness of antibody responses against P. falciparum sexual stage antigens Pfs230 and Pfs48/45 in individuals residing in an area of low endemicity in Tanzania after a recent malaria episode. Antibody prevalence and concentration were related to the duration of gametocyte exposure and showed a strong association with transmission- reducing activity (TRA).

The current study provided longitudinal data on sexual stage immune responses with repeated assessments of (functional) sexual stage immune responses shortly after a single malaria episode. Most previous studies on naturally acquired immune responses to P. falciparum sexual stage antigens relied on cross-sectional study designs [17,18,23,29,33,34,35,36,37], making it difficult to determine factors associated with the induction or persistence of sexual stage immune responses. To the best of our knowledge, only three studies have previously determined the acquisition and loss of sexual stage immune responses in longitudinal settings. These studies collected samples at 3- or 6-monthly intervals [19,24,38,39] and suggested that sexual stage antibody responses and functional TRA can be acquired rapidly [19] and may be more common in children than adults [23,24,39]. The current study focused on recently infected individuals and determined exposure to malaria parasites and immune responses in the weeks following a clinical episode, i.e. when there are potentially infectious gametocytes circulating against which transmission reducing immunity can act. Serological assessments were made at the time of first presentation with gametocytes and 4 and 12 weeks after enrolment, corresponding to 2–4 and 10–12 weeks after first presentation with gametocytes. None of the individuals in our cohort were re-infected with malaria parasites during 84-day follow-up. The prevalence and concentration of Pfs230 and Pfs48/45 antibodies were correlated with a longer duration of recent exposure to gametocytes. Less than 10% of the individuals who did not develop microscopically detectable gametocyte concentrations had antibodies against Pfs230 or Pfs48/45 one week after clearance of asexual parasitaemia. This proportion of seropositives showed a non-significant increase over time, which may be the result of immune-boosting by submicroscopic gametocyte densities that frequently accompany patent asexual parasite carriage and persist for several weeks [40,41,42] but were not measured in the current study. The use of molecular gametocyte detection methods, unavailable at the time, would have improved our study as some of the exposure to gametocyte antigens in our cohort will have been missed due to the limited sensitivity of microscopy for detecting low density gametocytaemia [9,42,43,44,45]. Submicroscopic infections were previously associated with the boosting of immune responses to schizont [46] and merozoite antigens [47] and it is therefore possible that sub-microscopic gametocyte densities may have had a similar immune-boosting effect in our study. Because only microscopy data were available, we were only able to test the association between exposure to relatively high, i.e. microscopically detectable, gametocyte densities and sexual stage immunity. There was a pronounced increase in sexual stage specific antibody prevalence and concentration in individuals who were exposed to microscopically detectable gametocyte densities during follow-up: more than one-third of individuals who carried gametocytes on at least two occasions during follow-up were positive for Pfs230 and Pfs48/45 antibodies four weeks after exposure to gametocytes. Previous studies often found no association between sexual stage immune responses and concurrent gametocyte prevalence or density [19,23,24,39], although the association is both biologically plausible and supported by indirect evidence from literature. For example, a study using immunoprecipitation for immune responses to Pfs230 and Pfg 27/25 observed variation in the intensity of bands in relation to malaria exposure, suggestive of immune boosting during the malaria season [39]. Similarly, Pfs230 and Pfs48/45 antibody prevalence and concentration increased with increasing recent exposure to malaria infections in Indonesian migrants exposed to malaria in hyperendemic Papua [19].

Sexual stage immune responses also increased with age in our cohort of parasite carriers. This study was not specifically designed to examine age related acquisition of immune responses and the sample size is insufficient to disprove observations from previous studies that showed that sexual stage immune responses do not increase with age [23,24,39]. However, age may well be a modulating factor in the acquisition or maintenance of sexual stage immune responses after (recent) exposure to sexual stage antigens. The prevalence of antibodies against Pfs230 and Pfs48/45 was higher in adults where they also appeared to have a longer half-life. More stable sexual stage immune responses in adults were previously reported in the Gambia [38]. There may be an innate difference between children and adults in how acquired immune systems function [48,49], resulting in more efficient immune response after recent exposure to sexual stage antigens. The prevalence of antibodies against Pfs230 and Pfs48/45 was higher in adults where they also appeared to have a longer half-life. More stable sexual stage immune responses in adults were previously reported in the Gambia [38]. There may be an innate difference between children and adults in how acquired immune systems function [48,49], resulting in more efficient immune response after recent exposure to sexual stage antigens. The prevalence of antibodies against Pfs230 and Pfs48/45 was higher in adults where they also appeared to have a longer half-life. More stable sexual stage immune responses in adults were previously reported in the Gambia [38].
needed to determine the longevity of antibody responses from long-lived plasma cells which may sustain low (but detectable) titres of antibodies for much longer periods. While the longevity of antibody responses is similar for sexual and asexual stages, our data nevertheless indicate clear differences in the kinetics of the two responses, consistent with differences in the timing of antigen exposure. Sexual stage immune responses increased in the first month of follow-up, following gametocyte exposure; asexual stage immune responses declined after asexual parasites were cleared and were not associated to gametocyte carriage.

We observed a strong association between the presence and concentration of sexual stage-specific antibody responses and functional TRA. Pf230 antibody-related TRA involves complement-mediated lysis of gametes [55]; Pf48/45 antibodies can inhibit zygote development independent of complement [56]. Serum samples with high reactivity to one or both of these antigens effectively reduced transmission. The observed association between Pf230 and Pf48/45 antibody prevalence and TRA was previously observed in field samples [23,24,34,35] but the association was particularly strong in the current dataset; 11/12 samples that showed TRA ≥90% were positive for both Pf48/45 and Pf230. The stronger association could be a consequence of using purified IgG rather than serum in the SMFA experiments, thereby reducing nonspecific effects of serum proteins. When we compared antibody concentration data with TRA, the association suggested a clear lower threshold of antibody concentrations above which high levels of TRA were assured. This resembles data from Pf25/Pvs25 vaccine studies in human volunteers and animal models where a clear lower threshold could be defined above which all serum samples reduced transmission by >50% [4,57].

The association of the could be partially explained by the study setting. We recruited individuals who were exposed to relatively low levels of malaria transmission and may therefore have less immunity to asexual antigens, which might cross-react with gametodes, reduce their infectivity [58] and thereby confound the association between sexual stage immune responses and TRA.

The association between sexual stage antibody responses and TRA may vary between settings [17,18,19,23,24,32,35,39,60]. In our study population, ~25% of all participants showed reactivity to Pf230 or Pf48/45. This proportion is similar to that found in gametocyte carriers from Tanzania [23] and Cameroon [17] and Tanzanian adults exposed to intense transmission intensity [24] but twofold lower than that reported in Sri Lankan individuals exposed to low level transmission intensity [60]. This underlines the necessity of carrying out longitudinal studies in areas with different transmission characteristics to determine the generality of our findings and determine whether the strong associations that we report can be extrapolated to other regions.

In conclusion, our data indicate that antibody responses to Pf230 and Pf48/45 are boosted by recent exposure to gametocytes and that increased antibody levels are associated with the duration of carriage of gametocytes. Our predicted half lives of sexual stage antibodies of 70–90 days are in broad agreement with the predicted half life of gametocyte carriage of 55 days [40]. However, antibody levels are correlated with TRA and the low antibody titres observed in the latter stages of infection may be insufficient to affect gametocyte infectivity of mosquitoes.

Acknowledgments

We thank the community and the village elders of Msitu wa Tembo for their cooperation. Thanks also to Alhuto Masokoto for slide reading and Paramo Lushino for field work. The study was conducted by the Joint Malaria Programme, a collaboration between the National Institute for Medical Research in Tanzania, Kilimanjaro Christian Medical Centre, London School of Hygiene and Tropical Medicine, and the University of Copenhagen.

Author Contributions

Conceived and designed the experiments: GT EMR CD. Performed the experiments: TB WR H. Meierink H. Mwinderi SMB GvBV FM CD. Analyzed the data: TB WR CD. Contributed reagents/materials/analysis tools: RS CD. Wrote the paper: TB GT EMR RS CD.

References

1. Ouchtourov NS, Roeflen W, Kaan A, Jansen J, Luty A, et al. (2006) Correctly folded Pf48/45 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in mice. Proc Natl Acad Sci U S A 103: 4301–4305.
2. Chowdhury DR, Angov E, Karinski T, Kumar N (2009) A potent malaria transmission blocking vaccine based on codon harmonized full length Pf48/45 expressed in Escherichia coli. PLoS One 4: e6352.
3. Cheru I, Wu Y, Diouf A, Moretz SE, Muratova OV, et al. (2010) The EC50 of anti-Pf25 antibody in membrane-feeding assay varies among species. Vaccine 28: 4423–4429.
4. Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin KM, et al. (2008) Phase 1 trial of malaria transmission blocking vaccine candidates Pf25 and Pvs25 formulated with montanide IS 31. PLoS One 3: e2636.
5. Tarrett GA, Greenwood BM (2008) Malaria vaccines and their potential role in the elimination of malaria. Malar J 7 Suppl 1: S10.
6. Sauerwein RW (2007) Malaria transmission-blocking vaccines: the bonus of effective malaria control. Microbes Infect 9: 792–795.
7. Schneider P, Bouma JT, Gouagna LC, Otaara S, van d’V, et al. (2007) Submicroscopic Plasmodium falciparum gametocyte densities frequently result in mosquito infection. Am J Trop Med Hyg 76: 470–474.
8. Graves PM (1980) Studies on the use of a membrane feeding technique for infecting Anopheles gambiae. Trans R Soc Trop Med Hyg 74: 730–742.
9. Ouedraogo AL, Bousma T, Schneider P, de Vlas SJ, Holoume-Sanogo E, et al. (2009) Substantial contribution of submicroscopic Plasmodium falciparum gametocyte carriage to the infectious reservoir in an area of seasonal transmission. PLoS One 4: e8410.
10. Targett G, Drakeley C, Jaswa M, von Seidlin I, Coleman R, et al. (2001) Antesumate reduces but does not prevent posttreatment transmission of Plasmodium falciparum to Anopheles gambiae. Journal of Infectious Diseases 183: 1254–1259.
11. Whitten MM, Shiao SH, Levashina EA (2006) Mosquito midguts and malaria: cell biology, compartmentalization and immunology. Parasite Immunol 28: 121–130.
12. Bouma JT, Drakeley CJ, Sauerwein RW (2006) Sexual-Stage Antibody Responses to P. falciparum in Endemic Populations. Curr Mol Med 6: 223–229.
13. Girard MP, Reed ZH, Friede M, Kienny MP (2007) A review of human vaccine research and development: malaria. Vaccine 25: 1567–1580.
14. Carter R, Mendis KN, Miller LH, Molinaux L, Saul A (2000) Malaria transmission-blocking vaccines—how can their development be supported? Nat Med 6: 241–244.
15. Eki S, Czesny B, van Gerner GT, Sauerwein RW, Elion W, et al. (2006) Malaria transmission-blocking antibody, Pf230, mediates human red blood cell binding to exflagellating male parasites and oocyst production. Mol Microbiol 61: 991–998.
16. Barton LA, Ranford-Cartwright LC (2005) Do malaria ookinete surface proteins P25 and P26 mediate parasite entry into mosquito midgut epithelial cells? Malar J 4: 15.
17. Roeflen W, Mulder B, Teelen K, Boliner M, Elion W, et al. (1996) Association between anti-Pf48/45 reactivity and P. falciparum transmission-blocking activity in sera from Cameroon. Parasite Immunology 18: 103–109.
18. Drakeley CJ, Elion W, Teelen K, Bouma JT, Sauerwein R, et al. (2004) Parasite infectivity and immunity to Plasmodium falciparum gametocytes in Gambian children. Parasite Immunol 26: 159–165.
19. Bouma JT, Roeflen W, Van Der KM, De Vlas SJ, Van DEV, et al. (2006) Rapid onset of transmission-reducing antibodies in Japanese migrants exposed to malaria in Papua Indonesia. Am J Trop Med Hyg 74: 425–431.
20. Ong CS, Zhang KY, Eida SJ, Graves PM, Dow C, et al. (1990) The primary antibody response of malaria patients to Plasmodium falciparum sexual stage antigens which are potential transmission blocking vaccine candidates. Parasite Immunol 12: 447–456.
21. Drakeley CJ, Corran PH, Coleman PG, Tongren JE, McDonald SL, et al. (2005) Estimating medium- and long-term trends in malaria transmission by using serological markers of malaria exposure. Proc Natl Acad Sci USA 102: 5108–5113.
22. Del Ghiude G, Lambert PH, Mendis K, Pessi A, Tanner M (1990) Antibody responses to Plasmodium falciparum and P. vivax sporozoites in areas with stable and unstable malaria. Bull World Health Organ 68 Suppl: 191–196.
23. Drakeley CJ, Bousema JT, Akim NJH, Teelen K, Roefen W, et al. (2006) Transmission reducing immunity is inversely related to age in P. falciparum gametocyte carriers. Parasite Immunology 28: 185–190.

24. Bousema JT, Drakeley CJ, Kihonda J, Hendriks JC, Akim NJ, et al. (2007) A longitudinal study of immune responses to Plasmodium falciparum sexual stage antigens in Tanzanian adults. Parasite Immunol 29: 309–317.

25. Oesterholt MJ, Bousema JT, Mwerinde OK, Harris C, Lushino P, et al. (2006) Spatial and temporal variation in malaria transmission in a low endemicity area in northern Tanzania. Malar J 5: 58.

26. Ponnudurai T, Lensen AH, Leeuwenberg AD, Meuwissen JH (1982) Cultivation of fertile Plasmodium falciparum gametocytes in semi-automated systems. 1. Static cultures. TransRoySocTropMedHyg 76: 812–818.

27. Corran PH, Cook J, Lynch C, Leendertse H, Manjurano A, et al. (2008) Dried blood spots as a source of anti-malarial antibodies for epidemiological studies. Malaria Journal 7: 195.

28. Lensen AH, van Druten J, Bolmer M, van Gemert G, Eling WM, et al. (2004) Evaluation of the standard membrane feeding assay (SMFA) for the determination of malaria transmission reducing activity using empirical data. Parasitology 129: 13–21.

29. Lensen A, van Druten J, Bolmer M, van Gemert G, Eling W, et al. (1996) Measurement by membrane feeding of reduction in Plasmodium falciparum transmission induced by endemic sera. TransRoySocTropMedHyg 90: 20–22.

30. van der Kolk M, de Vlas SJ, Sauerwein RW (2006) Reduction and enhancement of transmission induced by endemic sera. TransRSocTropMedHyg 90: 20–22.

31. Wipasa J, Sophaclai C, Okell LC, Cook J, Corran PH, et al. (2010) Long-lived antibody and B Cell responses to the human malaria parasites, Plasmodium falciparum and Plasmodium vivax. PLoS Pathog 6: e1000770.

32. Graves PM, Carter R, Burkot TR, Quakyi IA, Kumar N (1988) Antibodies to Plasmodium falciparum gamete surface antigens in Papua New Guinea sera. Parasite Immunol 10: 209–218.

33. Graves PM, Dubrovsky A, Carter R, Eida S, Beckers P (1990) High frequency of antibody response to Plasmodium falciparum gametocyte antigens during acute malaria infections in Papua New Guinea highlanders. American Journal of Tropical Medicine and Hygiene 42: 515–520.

34. Healer J, McGuinness D, Carter R, Riley E (1999) Transmission-blocking immunity to Plasmodium falciparum in malaria-immune individuals is associated with antibodies to the gamete surface protein Pfs230. Parasitology 119(Pt 5): 425–433.

35. Mulder B, Lensen T, Chuinkam T, Roefen W, Verhave JP, et al. (1999) Plasmodium falciparum: membrane feeding assays and competition ELISAs for the measurement of transmission reduction in sera from Cameroon. ExpParasitol 92: 81–86.

36. Roefen W, Lensen T, Mulder B, Teelen K, Sauwerin R, et al. (1994) Transmission blocking immunity as observed in a feeder system and serological reactivity to Pfs 48/43 and Pfs230 in field sera. MemInst Oswaldo Cruz 99 Suppl 21: 13–15.

37. Roefen W, Lensen T, Mulder B, Teelen K, Sauwerin R, et al. (1995) A comparison of transmission-blocking activity with reactivity in a Plasmodium falciparum 48/43/230 molecule-specific competition enzyme-linked immunosorbent assay. AmJTropMedHyg 52: 60–63.

38. Taylor RR, Egan A, McGuinness D, Jepson A, Adair R, et al. (1996) Selective recognition of malaria antigens by human serum antibodies is not genetically determined but demonstrates some features of clonal imprinting. Immunol Immunopathol 12: 905–915.

39. Taylor EM, Bennett S, Jepson A, Hassan-King M, Whittle H, et al. (1994) Human antibody responses to Pfs 230, a sexual stage-specific surface antigen of Plasmodium falciparum: non-responsiveness is a stable phenotype but does not appear to be genetically regulated. Parasite Immunol 16: 55–62.

40. Bousema T, Okell L, Shekalaghe S, Griffin JT, Omar S, et al. (2010) Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs. Malar J 9: 136.

41. Okell LC, Ghani AC, Lyons E, Drakeley CJ (2009) Submicroscopic infection in Plasmodium falciparum-endemic populations: a systematic review and meta-analysis. J Infect Dis 200: 1509–1517.

42. Ouedraogo AL, Schneider P, de Kruif M, Nebir I, Verhave JP, et al. (2007) Age-dependent distribution of Plasmodium falciparum gametocytes quantified by Pfs25 real-time QT-NASBA in a cross-sectional study in Burkina Faso. AmJTropMedHyg 76: 626–630.

43. Balâker HA, Schneider P, Reece SE (2008) Gametocytes: insights gained during a decade of molecular monitoring. Trends Parasitol 24: 525–530.

44. Bousema JT, Schneider P, Gouagna LC, Drakeley CJ, Testmann A, et al. (2006) Moderate Effect of Artemisinin-Based Combination Therapy on Transmission of Plasmodium falciparum. JInfectDis 193: 1151–1159.

45. Drakeley C, Sutherland E, Bousema JT, Sauerwein RW, TARGET GA (2006) The epidemiology of Plasmodium falciparum gametocytes: weapons of mass dispersion. Trends Parasitol 22: 424–430.

46. Giha HA, Naar A, Iriemenn NC, Balogun HA, Arnott D, et al. (2010) Age dependent association between IgG2 and IgG3 subclasses to Pfs230/C231 antigen and protection from malaria, and induction of protective antibodies by sub-patent malaria infections, in Darseewes. Vaccine 28: 1732–1739.

47. Shekalaghe S, Alifrangis M, Mwanziwa C, Enevold O, Mwakalinga S, et al. (2009) Low density parastasiaemia, red blood cell polymorphisms and Plasmodium falciparum specific immune responses in a low endemic area in northern Tanzania. BMC Infect Dis 9: 69.

48. Yasonbakhsh M, Sacks DJ (2010) Why does immunity to parasites take so long to develop? Nat Rev Immunol 10: 80–81.

49. Dushan DL, Dobano C, Baird JR (2009) Acquired immunity to malaria. Clin Microbiol Rev 22: 13–36.

50. Baird JK, Mashar S, Bari H, Tirtokasumo S, Subianto B, et al. (1998) Age-dependent susceptibility to severe disease with primary exposure to Plasmodium falciparum. Journal of Infectious Diseases 178: 592–595.

51. Baird JK (1995) Host Age as a determinant of naturally acquired immunity to Plasmodium falciparum. ParasitologyToday 11: 105–111.

52. Kinyanjui SM, Conway DJ, Lanar DE, Marsh K (2007) IgG antibody responses to Plasmodium falciparum merozoite antigens in Kenyan children have a short half-life. Malar J 6: 82.

53. Fonjungo PN, Ezhashi AM, Cavanagh DR, Theander TG, Hviid L, et al. (1999) A Longitudinal Study of Human Antibody Responses to Plasmodium falciparum Rhooptry-Associated Protein 1 in a Region of Seasonal and Unstable Malaria Transmission. Infection & Immunity 67: 2975–2985.

54. Akpogheneta OJ, Duah NO, Tetteh KK, Duno S, Lanar DE, et al. (2008) Duration of naturally acquired antibody responses to blood-stage Plasmodium falciparum is age dependent and antigen specific. Infect Immun 76: 1748–1755.

55. Healer J, McGuinness D, Hopcroft P, Haley S, Carter R, et al. (1997) Complement-mediated lysis of Plasmodium falciparum gametocytes by malaria-immune human sera is associated with antibodies to the gamete surface antigen Pfs230. Infect Immun 65: 3017–3023.

56. Carter R, Graves PM, Keister DB, Quakyi IA (1990) Properties of epitopes of Pfs 48/45, a target of transmission blocking monoclonal antibodies, on gametes of different isolates of Plasmodium falciparum. Parasite Immunol 12: 587–603.

57. Miura K, Keister DB, Maratova OV, Sattabongkot J, Long CA, et al. (2007) Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer. Malar J 6: 107.

58. Buckling A, Read AF (2001) The effect of partial host immunity on the transmission of malaria parasites. ProcBioSci 268: 2325–2330.

59. van der Kolk M, de Vlas SJ, Sauwerin RW (2006) Reduction and enhancement of Plasmodium falciparum transmission by endemic human sera. Int J Parasitol 36: 1091–1095.

60. Premawansa S, Garnage-Mendis A, Perera I, Begarnie S, Mendis K, et al. (1994) Plasmodium falciparum malaria transmission-blocking immunity under conditions of low endemicity as in Sri Lanka. Parasite Immunol 16: 35–42.